The following INS gene mutation was numbered incorrectly: In Figure 1 , Figure 2 , and section 6.1, we refer to the mutation V93L. This should have read as V92L. This does not affect the numbering of the other mutations, which remain correct. The corrected versions of Figures 1 and 2 are presented below. We apologize for this error.
Diagrammatic representation of the amino acid sequence of human preproinsulin (signal peptide-green, B-chain-red, C-peptideorange, A-chain-dark blue) indicating sites of mutations identified in patients with diabetes as well as hyperinsulinemia and hyperproinsulinemia. Mutations shown in black disrupt proinsulin folding and/or disulfide bond formation leading to permanent neonatal diabetesmellitus (PNDM); mutations in light blue do not impair folding but are associated with reduced insulin receptor binding potency (hyperinsulinaemia); mutations in light green are associated with hyperproinsulinaemia and either impair proteolytic processing to insulin or, in the case of H34D, aggregation and sorting into dense-core granules of the regulated secretory pathway. Mutations in pink and purple were found in patients with a diagnosis of maturity-onset diabetes of the young (MODY) and type 1b diabetes, respectively. The R55C mutation has been found in patients with a diagnosis of type 1b diabetes as well as MODY. The mutations shown in gray (A23S, A23T, L68M and G84R) are rare variants without functional effects on proinsulin/insulin biosynthesis. The mutations shown in yellow are recessive mutations that affect insulin biosynthesis (mutation of the translation initiation Met) or cause the synthesis of a nonsense protein (Q62X) 
